RT Journal Article
SR Electronic
T1 Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.25.21252477
DO 10.1101/2021.02.25.21252477
A1 Shinde, Vivek
A1 Bhikha, Sutika
A1 Hoosain, Zaheer
A1 Archary, Moherndran
A1 Bhorat, Qasim
A1 Fairlie, Lee
A1 Lalloo, Umesh
A1 Masilela, Mduduzi S. L.
A1 Moodley, Dhayendre
A1 Hanley, Sherika
A1 Fouche, Leon
A1 Louw, Cheryl
A1 Tameris, Michele
A1 Singh, Nishanta
A1 Goga, Ameena
A1 Dheda, Keertan
A1 Grobbelaar, Coert
A1 Kruger, Gertruida
A1 Carrim-Ganey, Nazira
A1 Baillie, Vicky
A1 de Oliveira, Tulio
A1 Koen, Anthonet Lombard
A1 Lombaard, Johan J.
A1 Mngqibisa, Rosie
A1 Bhorat, As’ad Ebrahim
A1 Benadé, Gabriella
A1 Lalloo, Natasha
A1 Pitsi, Annah
A1 Vollgraaff, Pieter-Louis
A1 Luabeya, Angelique
A1 Esmail, Aliasgar
A1 Petrick, Friedrich G.
A1 Jose, Aylin Oommen
A1 Foulkes, Sharne
A1 Ahmed, Khatija
A1 Thombrayil, Asha
A1 Fries, Lou
A1 Cloney-Clark, Shane
A1 Zhu, Mingzhu
A1 Bennett, Chijioke
A1 Albert, Gary
A1 Faust, Emmanuel
A1 Plested, Joyce S.
A1 Robertson, Andreana
A1 Neal, Susan
A1 Cho, Iksung
A1 Glenn, Greg M.
A1 Dubovsky, Filip
A1 Madhi, Shabir A.
A1 for the 2019nCoV-501 Study Group
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.02.25.21252477.abstract
AB Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the Covid-19 pandemic. Evaluation of Covid-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inform vaccine development and use.Methods In this phase 2a/b, multicenter, randomized, observer-blinded, placebo-controlled trial in South Africa, healthy human immunodeficiency virus (HIV)-negative adults (18 to 84 years) or medically stable people living with HIV (PLWH) (18 to 84 years) were randomized in a 1:1 ratio to receive two doses, administered 21 days apart, of either NVX-CoV2373 nanoparticle vaccine (5 µg recombinant spike protein with 50 µg Matrix-M1 adjuvant) or placebo. The primary endpoints were safety and vaccine efficacy ≥7 days following the second dose against laboratory-confirmed symptomatic Covid-19 in previously SARS-CoV-2 uninfected participants.Results A total of 4387 participants were randomized and dosed at least once, 2199 with NVX-CoV2373 and 2188 with placebo. Approximately 30% of participants were seropositive at baseline. Among 2684 baseline seronegative participants (94% HIV-negative; 6% PLWH), there were 15 and 29 predominantly mild to moderate Covid-19 cases in NVX-CoV2373 and placebo recipients, respectively; vaccine efficacy was 49.4% (95% confidence interval [CI]: 6.1 to 72.8). Efficacy in HIV-negative participants was 60.1% (95% CI: 19.9 to 80.1), and did not differ by baseline serostatus. Of the primary endpoint cases with available whole genome sequencing, 38 (92.7%) of 41 were the B.1.351 variant. Post-hoc vaccine efficacy against B.1.351 was 51.0% (95% CI: - 0.6 to 76.2) in HIV-negative participants. Among placebo recipients, the incidence of symptomatic Covid-19 was similar in baseline seronegative vs baseline seropositive participants during the first 2 months of follow-up (5.3% vs 5.2%). Preliminary local and systemic reactogenicity were primarily mild to moderate and transient, and higher with NVX-CoV2373; serious adverse events were rare in both groups.Conclusions The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, which was predominantly mild to moderate and due to the B.1.351 variant, while evidence of prior infection with the presumptive original SARS-CoV-2 did not confer protection against probable B.1.351 disease. (Funded by Novavax, The Bill and Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04533399)Competing Interest StatementDisclosure forms provided by the authors are available with the full text of this article at NEJM.org.Clinical TrialNCT04533399Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04533399?term=NVX-CoV2373+Covid-19+Vaccine&draw=2&rank=2 Funding StatementSupported by Novavax, Inc., The Bill and Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Innovations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the South African Health Products Regulatory Authority (SAHPRA; Ref 20200420) and Institutional Ethics Review Boards and registered in Clinicaltrials.gov (NCT04533399 and the Pan African Clinical trials Registry (PACTR202009726132275). Safety oversight, including for specific vaccination pause rules, was performed by an independent safety monitoring committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese are interim data, and individual participants remain masked to individual vaccine assignment. Therefore, it would be inappropriate to share individual level results at this time. https://clinicaltrials.gov/ct2/show/NCT04533399?term=NVX-CoV2373+Covid-19+Vaccine&draw=2&rank=2 http://www.novavax.com